Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 study of zuranolone (S-812217) in major depressive disorder
jRCT2080225180Phase 2Completed
- Sponsor
- Shionogi & Co., Ltd.
- Modality
- Allosteric Modulators → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2 trial of zuranolone in major depressive disorder (MDD), sponsored by Shionogi & Co., Ltd. Status: completed.
02
Drugs
zuranolone
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on jRCT2080225180.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080225180.